Based on these premises, the present work aims to determine whether the hERG1/β1 integrin complex localizes in LRs in cancer cells, from which it can trigger cancer-relevant signals, and whether such localization of the complex can be exploited for therapeutic purposes. This evidence concerns the gene KCNH2 and cancer.